Payment overview · 2025
General Payments
$362.41
16 reported records · 9 companies
Healthcare provider profile · identity verified
Ghiath Kashlan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TRINITY, FL · NPI 1053393561
Verified facts
What the public records show
CMS Open Payments records show Ghiath Kashlan, MD received $362.41 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.70 | 25.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.90 | 16.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.69 | 14.8% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $41.19 | 11.4% | 2 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $32.14 | 8.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.00 | 8.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.51 | 5.9% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $19.15 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.13 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $362.41 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.70 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.70 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $57.90 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.69 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $53.69 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $41.19 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 104 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 103 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 100 | 25 |
| Lisinopril | Lisinopril | 79 | 18 |
| Metformin Hcl | Metformin Hcl | 73 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 71 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 17 |
| Ozempic | Semaglutide | 63 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 14 |
| Trazodone Hcl | Trazodone Hcl | 58 | 18 |
| Gabapentin | Gabapentin | 51 | 17 |
| Losartan Potassium | Losartan Potassium | 51 | 13 |
| Montelukast Sodium | Montelukast Sodium | 51 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | 13 |
| Potassium Chloride | Potassium Chloride | 46 | 13 |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Eliquis | Apixaban | 40 | 11 |
| Simvastatin | Simvastatin | 40 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 12 |
| Carvedilol | Carvedilol | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 11 |
| Sertraline Hcl | Sertraline Hcl | 36 | 11 |
| Valsartan | Valsartan | 36 | suppressed |
| Lorazepam | Lorazepam | 33 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Finasteride | Finasteride | 31 | 11 |
| Glipizide | Glipizide | 31 | suppressed |
| Omeprazole | Omeprazole | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 24 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Celecoxib | Celecoxib | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $362.41 · 16 records | ABBVIE INC. | BRIXADI, Korlym, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SUBLOCADE, The Cologuard Plus Collection Kit, UBRELVY, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error